Complete Tophus Response in Patients with Chronic Gout Initiating Pegloticase Treatment

被引：0
|
作者：
Becker, Michael A. [2 ]
Gonter, Neil J. [1 ]
Pope, Janet E. [3 ]
Malamet, Raymond L. [4 ]
Baraf, Herbert S. B. [5 ]
机构：
[1] Rheumatol Associates N Jersey, Teaneck, NJ USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Univ Western Ontario, London, ON, Canada
[4] Savient Pharmaceut Inc, E Brunswick, NJ USA
[5] Arthrit & Rheumatism Associates, Wheaton, MD USA
来源：
ARTHRITIS AND RHEUMATISM | 2012年 / 64卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1913
引用
收藏
页码：S812 / S812
页数：1
相关论文
共 50 条
  • [21] Long-term safety of pegloticase in chronic gout refractory to conventional treatment
    Becker, Michael A.
    Baraf, Herbert S. B.
    Yood, Robert A.
    Dillon, Aileen
    Vazquez-Mellado, Janitzia
    Ottery, Faith D.
    Khanna, Dinesh
    Sundy, John S.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 (09) : 1469 - 1474
  • [22] Pegloticase: A guide to its use in treatment-refractory chronic gout in the EU
    Lyseng-Williamson K.A.
    Drugs & Therapy Perspectives, 2013, 29 (6) : 155 - 160
  • [23] Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
    Herbert SB Baraf
    Michael A Becker
    Sergio R Gutierrez-Urena
    Edward L Treadwell
    Janitzia Vazquez-Mellado
    Claudia D Rehrig
    Faith D Ottery
    John S Sundy
    Robert A Yood
    Arthritis Research & Therapy, 15
  • [24] Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
    Baraf, Herbert S. B.
    Becker, Michael A.
    Gutierrez-Urena, Sergio R.
    Treadwell, Edward L.
    Vazquez-Mellado, Janitzia
    Rehrig, Claudia D.
    Ottery, Faith D.
    Sundy, John S.
    Yood, Robert A.
    ARTHRITIS RESEARCH & THERAPY, 2013, 15 (05)
  • [25] New advances in the treatment of gout: review of pegloticase
    Reinders, Mattheus K.
    Jansen, Tim L. Th A.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2010, 6 : 543 - 550
  • [26] Pegloticase and the patient with treatment-failure gout
    Dave, Amish J.
    Kelly, Victoria M.
    Krishnan, Eswar
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2012, 5 (05) : 501 - 508
  • [27] Characterization of patients with chronic refractory gout who do and do not have clinically apparent tophi and their response to pegloticase
    Edwards, N. Lawrence
    Singh, Jasvinder A.
    Troum, Orrin
    Yeo, Anthony E.
    Lipsky, Peter E.
    RHEUMATOLOGY, 2019, 58 (08) : 1422 - 1431
  • [28] CHARACTERIZATION OF PATIENTS WITH CHRONIC REFRACTORY GOUT WHO DO AND DO NOT HAVE CLINICALLY APPARENT TOPHI: RESPONSE TO PEGLOTICASE
    Edwards, N. L.
    Singh, J.
    Troum, O.
    Yeo, A.
    Lipsky, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 377 - 377
  • [29] The Impact of Azathioprine on the Frequency of Persistent Responsiveness to Pegloticase in Patients with Chronic Refractory Gout
    Baraf, Herbert S.
    Rainey, Hope
    Lipsky, Peter
    Lipsky, Peter
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [30] Reversal of chronic refractory tophaceous gout with erosions with pegloticase
    Yeter, Karen C.
    Ortiz, Elizabeth C.
    Arkfeld, Daniel G.
    INTERNATIONAL JOURNAL OF RHEUMATIC DISEASES, 2013, 16 (03) : 369 - 370
12345